Endocrinology

Top Medical News
fructose consumption tied to more liver fat
2 days ago
Consumption of fructose from sweetened beverages contributes to unfavourable profiles of several cardiometabolic biomarkers, reveals a study.
SGLT2 - renal & respiratory outcomes
Kanas Chan, 4 days ago
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risks of respiratory and renal diseases vs dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM), researchers from the University of Hong Kong (HKU) have reported.
CGM improves glycaemic, neonatal outcomes in pregnant women with T1D
4 days ago
Combining continuous glucose monitoring (CGM) with continuous subcutaneous insulin infusion (CSII) therapy helps keep blood glucose levels low throughout pregnancy and lower the rate of large for gestational age (LGA) delivery, according to a study.
Sleep loss ups hunger-promoting hormones in adults
25 Mar 2023
A recent study has shown that acute sleep deprivation leads to a decrease in blood concentrations of satiety-hormone leptin and to an increase in ghrelin and adiponectin, which induce hunger.
BMI drives causal relationship of sleep apnoea, snoring with T2D
24 Mar 2023
Body mass index (BMI) appears to be the main mediator of the association of sleep apnoea and snoring with type 2 diabetes (T2D), suggests a study.
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
24 Mar 2023
Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.
Time-restricted eating offers no additional benefits in adults with obesity, NAFLD
24 Mar 2023
Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.
Special Reports
EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute he
21 Mar 2023
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Clinical benefits of flash glucose monitoring with FreeStyle Libre™
15 Sep 2021
Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.
Conference Reports
ESSENTIAL: Ezetimibe plus statin reduces liver fat
Elvira Manzano, 31 Oct 2022
Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.
Hysterectomy tied to increased diabetes risk
Roshini Claire Anthony, 21 Oct 2022

Undergoing a hysterectomy, particularly at a young age, may be associated with an increased risk of developing diabetes, according to a study from France presented at EASD 2022.

Beta-blocker shows potential for diabetic foot ulcers
Audrey Abella, 20 Oct 2022
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
Sotagliflozin may offer cardiorenal protection for adults with T1D
Audrey Abella, 13 Oct 2022
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Triple-drug combo reduces HbA1c in T2D
Elaine Soliven, 12 Oct 2022
Adding evogliptin, a novel dipeptidyl peptidase-4 inhibitor, to dapagliflozin and metformin significantly reduced HbA1c level in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2022.
Young age at diabetes diagnosis tied to worse outcomes
Roshini Claire Anthony, 09 Oct 2022

Individuals who are diagnosed with type 2 diabetes (T2D) at age 40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

Tirzepatide confers renal protection in patients with T2D
Elaine Soliven, 05 Oct 2022
Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.